The Seven-membered Hetero Ring Shares Ring Members With One Other Cyclo Only Patents (Class 540/580)
-
Patent number: 7022694Abstract: The present invention provides compounds of Formula (I): wherein R1, R2, R3, R4, R5, R6 and --- have any of the values defined in the specification, as well as pharmaceutical compositions comprising the compounds. The invention also provides therapeutic methods as well as processes and intermediates useful for preparing compounds of Formula (I). The compounds are useful as 5-HT ligands.Type: GrantFiled: July 11, 2002Date of Patent: April 4, 2006Assignee: Pharmacia & UpJohn CompanyInventors: Jian-Min Fu, Jeanette Kay Morris, Arthur Glenn Romero
-
Patent number: 6933304Abstract: The present invention relates to a class of compounds represented by the Formula I or a pharmaceutically acceptable salt thereof, pharmaceutical compositions comprising compounds of the Formula I, and methods of selectively antagonizing the ?V?3 and/or the ?V?5 integrin without significantly antagonizing the IIb/IIIa or ?V?6 integrin.Type: GrantFiled: June 15, 2001Date of Patent: August 23, 2005Assignee: Pharmacia CorporationInventors: Srinivasan Raj Nagarajan, Ish Kumar Khanna, Michael B. Tollefson, Scott B. Mohler, Barbara Chen, Mark Russell, Balekudru Devadas, Thomas D. Penning, Lori A. Schretzman, Dale P. Spangler, Mark Laurence Boys, Nizal Samuel Chandrakumar, Hung-Fun Lu
-
Patent number: 6921823Abstract: The present invention are substituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (X) and unsubstituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (XI) such as the compound of EXAMPLE 13 which are useful in treating depression, obesity and other CNS disorders.Type: GrantFiled: October 30, 2001Date of Patent: July 26, 2005Assignee: Pharmacia & Upjohn Company LLCInventors: Eric Jon Jacobsen, Susan Fox Jacobsen
-
Patent number: 6903090Abstract: Disclosed are compounds of Formula (I): wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.Type: GrantFiled: March 20, 2003Date of Patent: June 7, 2005Assignee: PfizerInventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-min Fu, William W. McWhorter, Jr., Jeanette K. Morris, Donald Joseph Rogier, Eric Jon Jacobsen
-
Patent number: 6828314Abstract: The invention provides compounds of Formula (I): wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.Type: GrantFiled: March 20, 2003Date of Patent: December 7, 2004Assignee: PfizerInventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-min Fu, Eric Jon Jacobsen, William W. McWhorter, Jr., Jeanette K. Morris, Donald Joseph Rogier
-
Patent number: 6777406Abstract: The present invention is directed to certain novel compounds represented by structural Formula (I) or pharmaceutically acceptable salt forms thereof, wherein is R1, R6a, R6b, R7, R8, R9, X, b, m, and n are described herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are serotonin agonists and antagonists and are useful in the control or prevention of central nervous system disorders including obesity, anxiety, depression, psychosis, schizophrenia, sleep disorders, sexual disorders, migraine, conditions associated with cephalic pain, social phobias, and gastrointestinal disorders such as dysfunction of the gastrointestinal tract motility.Type: GrantFiled: December 19, 2001Date of Patent: August 17, 2004Assignee: Bristol-Myers Squibb Pharma CompanyInventors: John M. Fevig, Ian S. Mitchell, Taekyu Lee, Wenting Chen, Joseph Cacciola
-
Publication number: 20040054170Abstract: The present invention discloses radioligands of 9-arylsulfone of the formula (X) 1Type: ApplicationFiled: April 25, 2003Publication date: March 18, 2004Inventors: Eric Jon Jacobsen, Kalpana M. Merchant
-
Patent number: 6699989Abstract: Disclosed are guanidine and biguanidine derivatives which have anti-viral and anti-bacterial activity. Also disclosed are pharmaceutical compositions containing such compounds as an active ingredient, and anti-viral and anti-bacterial methods utilizing such compounds.Type: GrantFiled: August 28, 2000Date of Patent: March 2, 2004Inventor: B. Vithal Shetty
-
Patent number: 6693101Abstract: The present invention relates to novel alkanoic acid derivatives thereof, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammatory arthritis, cancer, and metastatic tumor growth.Type: GrantFiled: January 23, 2001Date of Patent: February 17, 2004Assignee: Merck & Co., Inc.Inventors: Ben C. Askew, Michael J. Breslin, Mark E. Duggan, John H. Hutchinson, Robert S. Meissner, James J. Perkins, Thomas G. Steele, Michael A. Patane
-
Publication number: 20040023946Abstract: Novel substituted hexahydropyrrolo[1,2-a]pyrazines, octahydropyrido[1 ,2-a]-pyrazines and decahydropyrazino[1,2-a]azepines, use of these compounds as pharmaceutical compositions, pharmaceutical compositions comprising the compounds, and a method of treatment employing these compounds and compositions. The compounds show a high and selective binding affinity to the histamine H3 receptor indicating histamine H3 receptor antagonistic, inverse agonistic or agonistic activity. As a result, the compounds are useful for the treatment of diseases and disorders related to the histamine H3 receptor.Type: ApplicationFiled: June 3, 2003Publication date: February 5, 2004Inventors: Bernd Peschke, Rolf Hohlweg
-
Publication number: 20030225058Abstract: The invention provides compounds of Formula (I): 1Type: ApplicationFiled: March 20, 2003Publication date: December 4, 2003Applicant: Pharmacia & UpJohn CompanyInventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-Min Fu, Eric Jon Jacobsen, William W. McWhorter, Jeanette K. Morris, Donald Joseph Rogier
-
Publication number: 20030220321Abstract: Disclosed are compounds of Formula (I): 1Type: ApplicationFiled: March 20, 2003Publication date: November 27, 2003Applicant: Pharmacia & UpJohn CompanyInventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-Min Fu, William W. McWhorter, Jeanette K. Morris, Donald Joseph Rogier, Eric Jon Jacobsen
-
Patent number: 6642222Abstract: The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.Type: GrantFiled: May 3, 2000Date of Patent: November 4, 2003Assignee: Abbott LaboratoriesInventors: William A. Carroll, Konstantinos A. Agrios, Robert J. Altenbach, Irene Drizin, Michael E. Kort
-
Patent number: 6586421Abstract: The invention provides compounds of Formula (I): wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.Type: GrantFiled: September 20, 2001Date of Patent: July 1, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-min Fu, Eric Jon Jacobsen, William W. McWhorter, Jr., Jeanette K. Morris, Donald Joseph Rogier
-
Patent number: 6583135Abstract: Disclosed are compounds of Formula (I): wherein R1-R4, p and q have any of the values described in the specification, as well as pharmaceutical salts thereof, and pharmaceutical compositions containing such compounds or salts. The compounds and salts are 5-HT ligands and are useful for treating diseases, disorders, and/or conditions in a mammal wherein activity of a 5-HT receptor is implicated. The compounds and salts are particularly useful for treating diseases of the central nervous system.Type: GrantFiled: September 20, 2001Date of Patent: June 24, 2003Assignee: Pharmacia & Upjohn CompanyInventors: Kristine E. Frank, Brad A. Acker, Michael D. Ennis, Jed F. Fisher, Jian-min Fu, William W. McWhorter, Jr., Jeanette K. Morris, Donald Joseph Rogier, Eric Jon Jacobsen
-
Patent number: 6583134Abstract: Novel compounds of formula (I): wherein X1, X2, X3 and X4, n, R1, R2 and R3 are defined in the specification, and pharmaceutically acceptable salts and prodrugs of the compounds of formula (I) have therapeutic uses. These compounds are useful for the treatment of disorders of the central nervous system; damage to the central nervous system; cardiovascular disorders; gastrointestinal disorders; diabetes insipidus, and sleep apnea. They are particularly useful for the treatment of obesity.Type: GrantFiled: February 27, 2001Date of Patent: June 24, 2003Assignees: Hoffman-La Roche Inc., Vernalis Research LimitedInventors: Jonathan Mark Bentley, Paul Hebeisen, Sven Taylor
-
Publication number: 20030055035Abstract: 1Type: ApplicationFiled: May 3, 2000Publication date: March 20, 2003Inventors: Willilam A. Carroll, Konstantinos A. Agrios, Robert J. Altenbach, Irene Drizin, Michael E. Kort
-
Patent number: 6534650Abstract: This invention relates to compounds of Formula V H—Y—G—R V and Formula VI (wherein f, X, Y, G and R have the values defined in the description) which are useful as intermediates for the preparation of compounds, or pharmaceutically acceptable salts thereof, which are useful as thrombin inhibitors, coagulation inhibitors and agents for the treatment of thromboembolic disorders.Type: GrantFiled: March 9, 2001Date of Patent: March 18, 2003Assignee: Eli Lilly and CompanyInventors: Valentine J Klimkowski, Aaron L Schacht, Michael R Wiley
-
Publication number: 20020193589Abstract: This invention discloses and claims a series of mercaptoacetylamide derivatives of formula I. Also disclosed and claimed are pharmaceutical compositions incorporating these compounds and processes for preparing said compounds. The use of said compounds for inhibition of the enzymes angiotensin converting enzyme and neutral endopeptidase, and for the treatment of hypertension and congestive heart failure are also disclosed and claimed.Type: ApplicationFiled: April 8, 2002Publication date: December 19, 2002Inventors: Gary A. Flynn, Barbara A. Anderson, Manfred Gerken, Bernd Jablonka, Heinz-Werner Kleemann, Wolfgang Linz, Werner Seiz, Bernhard Seuring
-
Patent number: 6468999Abstract: The present invention are substituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (X) and unsubstituted 9-arylsulfone-1,2,3,4,5,6-hexahydroazepino[4,5-b]indoles (XI) such as the compound of EXAMPLE 13 which are useful in treating depression, obesity and other CNS disorders.Type: GrantFiled: July 11, 2000Date of Patent: October 22, 2002Assignee: Pharmacia & Upjohn CompanyInventors: Eric Jon Jacobsen, Susan Korynne Hendges
-
Patent number: 6465507Abstract: The invention relates to certain indolinone compounds, their method of synthesis, and a combinatorial library consisting of the indolinone compounds of the invention. The invention also relates to methods of modulating the function of protein kinases using indolinone compounds of the invention and methods of treating diseases by modulating the function of protein kinases and related signal transduction pathways.Type: GrantFiled: February 28, 2001Date of Patent: October 15, 2002Assignee: Sugen, Inc.Inventors: Peng Cho Tang, Todd A. Miller, Xiaoyuan Li, Ruofei Zhang, Jinrong Cui, Ping Huang, Chung Chun Wei
-
Patent number: 6410526Abstract: The present invention relates to novel nonanoic acid derivatives, their synthesis, and their use as &agr;v integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.Type: GrantFiled: May 31, 2000Date of Patent: June 25, 2002Assignee: Merck & Co., Inc.Inventors: Mark E. Duggan, George D. Hartman, Robert S. Meissner, James J. Perkins
-
Publication number: 20020058652Abstract: The present invention relates to aryl olefinic azacyclic compounds and aryl acetylenic azacyclic compounds, including pyridyl olefinic cycloalkylamines and pyridyl acetylenic cycloalkylamines. The present invention also relates to prodrug derivatives of the compounds of the present invention.Type: ApplicationFiled: April 30, 2001Publication date: May 16, 2002Inventors: Gary Maurice Dull, Jeffrey Daniel Schmitt, Balwinder Singh Bhatti, Craig Harrison Miller
-
Patent number: 6369222Abstract: The invention relates to nitro- and cyano-1,2,4,5-tetrahydro-heterocycloazepinyl pyrimidine derivatives as well as their pharmaceutically acceptable salts. The invention further relates to medicaments containing such compounds and a process for the preparation of such compounds. The compounds of the invention are group I mGluR antagonists and are therefore useful for the control or prevention of acute and/or chronic neurological disorders.Type: GrantFiled: July 11, 2001Date of Patent: April 9, 2002Assignee: Hoffmann-La Roche Inc.Inventors: Alfred Binggeli, Hans-Peter Maerki, Vincent Mutel, Wolfgang Wostl
-
Patent number: 6191140Abstract: The present invention provides novel compounds of formula I which may be useful in hyperpolarizing cell membranes, opening potassium channels, relaxing smooth muscle cells, and inhibiting bladder contractions.Type: GrantFiled: October 20, 1999Date of Patent: February 20, 2001Assignee: Abbott LaboratoriesInventors: William A. Carroll, Konstantinos A. Agrios, Robert J. Altenbach, Irene Drizin, Michael E. Kort
-
Patent number: 6180640Abstract: The present invention provides methods and pharmaceutical preparations that inhibit the growth of bacterial microorganisms. Additionally, the present invention provides methods and pharmaceutical preparations that kill bacterial microorganisms.Type: GrantFiled: June 25, 1999Date of Patent: January 30, 2001Assignee: Sepracor, Inc.Inventors: Gregory D. Cuny, James R. Hauske, Michael Z. Hoemann, Richard F. Rossi, Roger L. Xie
-
Patent number: 6136968Abstract: Described are novel reversible photochromic compounds of the homoazaadamantane spirooxazine family. Certain substituents are present on the nitrogen atom of the homoazaadamantane portion of the compound and on the benzene ring fused to the oxazine portion of the compound. These compounds may be represented by the following formula: Also described are compositions, e.g., solvent based mediums and polymerized organic materials, used to produce ophthalmic components, that contain the homoazaadamantane compounds with or without other photochromic compounds.Type: GrantFiled: January 29, 1999Date of Patent: October 24, 2000Assignee: Transitions Optical Inc.Inventors: Karine Chamontin, Vladimir Lokshin, Andre Samat, Robert Guglielmetti
-
Patent number: 6048854Abstract: The present invention relates to a 2,3-diaminopropionic acid derivative of the formula (1): ##STR1## or a pharmaceutically acceptable salt thereof. The compounds of the present invention are useful as a platelet aggregation inhibitor, a cancer metastasis inhibitor, a wound healing agent or a bone resorption inhibitor.Type: GrantFiled: September 25, 1997Date of Patent: April 11, 2000Assignee: Sumitomo Pharmaceuticals Company, LimitedInventors: Yoshiharu Ikeda, Yasuyuki Ueki, Hisakazu Kishimoto, Toshio Nishihara, Yumiko Kamikawa
-
Patent number: 6043238Abstract: A compound of the formula ##STR1## wherein a, V, X, Y, Z, R.sup.1, R.sup.2, R.sup.3 and R.sup.4 are as defined above, useful in (a) the treatment of myelosuppression including suppression associated with cancer chemotherapy as well as activation of the immune system for the treatment of cancer or (b) prevention and treatment of viral, fungal, bacterial and parasitic infectious diseases.Type: GrantFiled: August 15, 1997Date of Patent: March 28, 2000Assignee: Pfizer Inc.Inventors: Christopher B. Cooper, Joseph P. Lyssikatos, Donald W. Mann, Scott J. Hecker
-
Patent number: 5968929Abstract: The invention relates to compounds of the formula ##STR1## wherein Z, R.sub.c, y, m, u, Ar.sub.2, n, X, R.sub.c', l and Ar.sub.2 are as described herein. These compounds are neurokinin antagonists. These compounds are useful in the treatment of chronic airway diseases such as asthma.Type: GrantFiled: October 28, 1997Date of Patent: October 19, 1999Assignee: Schering CorporationInventors: David J. Blythin, Xiao Chen, Richard J. Friary, Kevin D. McCormick, John J. Piwinski, Neng-Yang Shih, Ho-Jane Shue
-
Patent number: 5945431Abstract: The present invention relates to heterocyclic compounds having antiviral activity. In particular, compounds of formula (I): wherein B, W, X, Y, R.sub.1, R.sub.2, R.sub.3, R.sub.4 and n are as defined herein, are useful in the therapy and prophylaxis of cytomegalovirus (CMV) infection in mammals.Type: GrantFiled: September 4, 1997Date of Patent: August 31, 1999Assignee: Biochem Therapeutics IncorporatedInventors: Haolun Jin, Laval C. Chan, Wei Wang, Tomislav Stefanac, Tarek S. Mansour, Paul Nguyen-Ba, Jean-Francois Lavallee, Guy Falardeau
-
Patent number: 5929085Abstract: There are provided novel compounds of formula (I) ##STR1## wherein X, R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are as defined in the specification and optical isomers and racemates thereof and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy.Type: GrantFiled: January 22, 1997Date of Patent: July 27, 1999Assignee: Astra AktiebolagInventors: James MacDonald, James Matz, William Shakespeare
-
Patent number: 5837868Abstract: A process for the preparation of chiral 3-aminopyrrolidine and analogous bicyclic derivatives from dihydroxy olefins by treatment with titanium isopropoxide, an optically active tartrate ester and tert-butyl hydroperoxide, followed by subsequent alkylation of the intermediate with an alkyl or alkenyl magnesium halide, then pyrrolidine ring formation by condensation with an arylmethylamine, subsequent chiral replacement of a ring hydroxyl group with an amino group with further protection thereof, optional additional substitution closing of the second ring, and hydrogenolysis to remove a ring-nitrogen protecting group.Type: GrantFiled: November 19, 1997Date of Patent: November 17, 1998Assignee: Abbott LaboratoriesInventors: Wei-Bo Wang, Qun Li, Daniel T. Chu, Lisa Anne Hasvold
-
Patent number: 5780493Abstract: The present patent application discloses compounds having formula (I) or a pharmaceutically acceptable salt thereof wherein R.sup.1 is hydrogen, alkyl or benzyl; X is O or NOR.sup.2, wherein R.sup.2 is hydrogen, alkyl or benzyl; Y is N--R.sup.4 wherein R.sup.4 is hydrogen, OH or alkyl; n is 0 or 1; R.sup.6 is phenyl, naphthyl, thienyl, pyridyl, all of which may be substituted one or more times with substituents selected from the group consisting of halogen; CF.sub.3, NO.sub.2, amino, alkyl, alkoxy and phenyl; A is a ring of five to seven atoms fused with the benzo ring at the positions marked a and b. The compounds are useful in the treatment of cerebrovascular disorders for example.Type: GrantFiled: October 16, 1997Date of Patent: July 14, 1998Assignee: NeuroSearch A/SInventors: Frank Watjen, Jorgen Drejer
-
Patent number: 5674863Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.Type: GrantFiled: May 26, 1995Date of Patent: October 7, 1997Assignee: Genentech, Inc.Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
-
Patent number: 5674865Abstract: A benzodiazepinedione derivative which acts as a nonpeptidyl platelet aggregation inhibitor is provided. This inhibitor potently inhibits fibrinogen binding to the GPII.sub.b III.sub.a receptor and is provided in therapeutic compositions for the treatment of diseases for which blocking platelet aggregation is indicated. These nonpeptidyl inhibitors are provided in combination with thrombolytics and anticoagulants.Type: GrantFiled: May 26, 1995Date of Patent: October 7, 1997Assignee: Genentech, Inc.Inventors: Brent Blackburn, Peter Barker, Thomas Gadek, Robert McDowell, Lawrence McGee, Todd Somers, Rob Webb, Kirk Robarge
-
Patent number: 5658921Abstract: The subject invention describes Novel dimer 4-phenylpiperidine, 4-phenyl-1,2,3,6-tetrahydropyridine, or 4-phenylpiperazine compounds or dimeric spirocyclic piperidine compounds having the general Formula I: ##STR1## wherein n is 1-5;R.sup.1 to R.sup.4 are independently selected from hydrogen, halogen, C.sub.1-6 alkyl, C.sub.1-6 alkoxy, hydroxy, C.sub.1-6 alkylthio, C.sub.1-6 alkylsulfonyl, C.sub.1-6 alkyl- or di-(C.sub.1-6 alkyl)amino, cyano, trifluoromethyl, nitro, trifluoromethylthio or trifluoromethylsulfonyloxy; R.sup.5 and R.sup.6 are independently hydrogen, or C.sub.1-6 alkyl;X is O, S, SO, SO.sub.2, CO or (CH.sub.2).sub.m, m being 0 or 1, or X is NR.sup.7, R.sup.7 being H, C.sub.1-6 alkyl, cycloalkyl, cycloalkylalkyl, phenyl, or phenylalkyl, or X is CR.sup.8 R.sup.9, wherein R.sup.8 and R.sup.9 are independently selected from the group consisting of hydroxy and the substituents defined under R.sup.7, any phenyl group being optionally substituted with one or more substituents selected from halogen, C.Type: GrantFiled: December 12, 1994Date of Patent: August 19, 1997Assignee: H. Lundbeck A/SInventors: Jens Perregaard, John W. Stenberg, Ejner K. Moltzen
-
Patent number: 5641771Abstract: The invention generally relates to compounds of the formula I, which are in equilibrium with their 4-hydroxy tautomers, and their pharmaceutically acceptable salts: ##STR1## where n is 0 to 2; A is S, CH.sub.2, O, NH or Se, and when n is 0, A is not CH.sub.2, and when n is 1, A is not CH.sub.2 or NH; X is a substituted or unsubstituted C.sub.1 -C.sub.3 alkyl, C.sub.2 -C.sub.3 alkenyl, C.sub.2 -C.sub.3 alkynyl or amino, or sulfur or oxygen; Ar is a substituted or unsubstituted monocyclic carbocycle or heterocycle, or fused or nonfused polycyclic carbocycle or heterocycle; and R.sub.1 and R.sub.2 are hydrogen or a moiety that forms together with the attached CO.sub.2 a readily hydrolyzable ester group. These compounds and their salts are useful as inhibitors of GARFT or as antiproliferative agents. The invention also pertains to pharmaceutical compositions and methods employing such compounds as GARFT inhibitors or antiproliferative agents.Type: GrantFiled: June 7, 1995Date of Patent: June 24, 1997Assignee: Agouron Pharmaceuticals, Inc.Inventors: Michael D. Varney, William H. Romines, Cynthia L. Palmer
-
Patent number: 5641774Abstract: The invention generally relates to compounds of the formula I, which are in equilibrium with their 4-hydroxy tautomers, and their pharmaceutically acceptable salts: ##STR1## where n is 0 to 2; A is S, CH.sub.2, O, NH or Se, and when n is 0, A is not CH.sub.2, and when n is 1, A is not CH.sub.2 or NH; X is a substituted or unsubstituted C.sub.1 --C.sub.3 alkyl, C.sub.2 -C.sub.3 alkenyl, C.sub.2 -C.sub.3 alkynyl or amino, or sulfur or oxygen; Ar is a substituted or unsubstituted monocyclic carbocycle or heterocycle, or fused or nonfused polycyclic carbocycle or heterocycle; and R.sub.1 and R.sub.2 are hydrogen or a moiety that forms together with the attached CO.sub.2 a readily hydrolyzable ester group. These compounds and their salts are useful as inhibitors of GARFT or as antiproliferative agents. The invention also pertains to pharmaceutical compositions and methods employing such compounds as GARFT inhibitors or antiproliferative agents.Type: GrantFiled: June 7, 1995Date of Patent: June 24, 1997Assignee: Agouron Pharmaceuticals, Inc.Inventors: Michael D. Varney, William H. Romines, Cynthia L. Palmer
-
Patent number: 5639747Abstract: The invention generally relates to compounds of the formula I, which are in equilibrium with their 4-hydroxy tautomers, and their pharmaceutically acceptable salts: ##STR1## where n is 0 to 2; A is S, CH.sub.2, O, NH or Se, and when n is 0, A is not CH.sub.2, and when n is 1, A is not CH.sub.2 or NH; X is a substituted or unsubstituted C.sub.1 -C.sub.3 alkyl, C.sub.2 -C.sub.3 alkenyl, C.sub.2 -C.sub.3 alkynyl or amino, or sulfur or oxygen; Ar is a substituted or unsubstituted monocyclic carbocycle or heterocycle, or fused or nonfused polycyclic carbocycle or heterocycle; and R.sub.1 and R.sub.2 are hydrogen or a moiety that forms together with the attached CO.sub.2 a readily hydrolyzable ester group. These compounds and their salts are useful as inhibitors of GARFT or as antiproliferative agents. The invention also pertains to pharmaceutical compositions and methods employing such compounds as GARFT inhibitors or antiproliferative agents.Type: GrantFiled: June 7, 1995Date of Patent: June 17, 1997Assignee: Agouron Pharmaceuticals, Inc.Inventors: Michael D. Varney, William H. Romines, Cynthia L. Palmer
-
Patent number: 5639749Abstract: The invention generally relates to compounds of the formula I, which are in equilibrium with their 4-hydroxy tautomers, and their pharmaceutically acceptable salts: ##STR1## where n is 0 to 2; A is S, CH.sub.2, O, NH or Se, and when n is 0, A is not CH.sub.2, and when n is 1, A is not CH.sub.2 or NH; X is a substituted or unsubstituted C.sub.1 -C.sub.3 alkyl, C.sub.2 -C.sub.3 alkenyl, C.sub.2 -C.sub.3 alkynyl or amino, or sulfur or oxygen; Ar is a substituted or unsubstituted monocyclic carbocycle or heterocycle, or fused or nonfused polycyclic carbocycle or heterocycle; and R.sub.1 and R.sub.2 are hydrogen or a moiety that forms together with the attached CO.sub.2 a readily hydrolyzable ester group. These compounds and their salts are useful as inhibitors of GARFT or as antiproliferative agents. The invention also pertains to pharmaceutical compositions and methods employing such Compounds as GARFT inhibitors or antiproliferative agents.Type: GrantFiled: June 7, 1995Date of Patent: June 17, 1997Assignee: Agouron Pharmaceuticals, Inc.Inventors: Michael D. Varney, William H. Romines, Cynthia L. Palmer
-
Patent number: 5512562Abstract: Tricyclic benzazepines having the general formula ##STR1## wherein A together with the .alpha.- and .beta.-marked carbon atoms is a cyclopentene, cyclohexene, furan, dihydrofuran, pyran, dihydropyran, thiophene, oxazole, pyrrole, pyrroline, tetrahydropyridine or dioxole ring, R.sup.1 is H or alkyl, R.sup.2 and R.sup.3 independently are H, alkoxy, halogen, nitro, cyano or hydroxy, or R.sup.2 and R.sup.3 together may form a furan, dihydrofuran, cyclopentene or dioxole ring and R.sup.4 is H, alkoxy, nitro, cyano, hydroxy or halogen, or a pharmaceutically acceptable salt thereof, are useful in treatment of certain disorders in the central nervous system, e.g., psychosis, pain, depression, sleep disturbances, dyskinesia, Parkinson's disease, stroke.Type: GrantFiled: February 24, 1994Date of Patent: April 30, 1996Assignee: Novo Nordisk A/SInventors: Rolf Hohlweg, Erik B. Nielsen
-
Patent number: 5399557Abstract: This invention provides a pyrroloazepine compound represented by the following formula (I) or (II): ##STR1## wherein Z.sub.1, Z.sub.2, R, A and Y are defined in the claims. The pyrroloazepine compounds according to the present invention are drugs having excellent anti-serotonin action. Coupled with their high safety, they can therefore be used as novel therapeutics for ischemic heart diseases. In addition, the compounds of the present invention include those having anti-.alpha..sub.1 action. Such compounds are effective as hypotensive drugs. Pyrroloazepine compounds according to the present invention are therefore extremely useful as therapeutics for a wide variety of circulatory diseases.Type: GrantFiled: April 7, 1993Date of Patent: March 21, 1995Assignee: Suntory LimitedInventors: Akira Mizuno, Mikiko Miya, Norio Inomata, Toshio Tatsuoka, Takafumi Ishihara
-
Patent number: 5399553Abstract: A tricyclic compound represented by the general formula (1) and salts thereof are disclosed. ##STR1## A method for producing the tricyclic compound and salts thereof, and an antimicrobial agent containing the tricyclic compound and salts thereof as an active ingredient are also disclosed.Type: GrantFiled: June 16, 1993Date of Patent: March 21, 1995Assignees: Wakunaga Seiyaku Kabushiki Kaisha, Fujisawa Pharmaceutical Company, Ltd.Inventors: Masaharu Yokomoto, Akira Yazaki, Norihiro Hayashi, Shunso Hatono, Satoshi Inoue, Yasuhiro Kuramoto
-
Patent number: 5389629Abstract: There are disclosed compounds having the formula ##STR1## wherein n is 1-4; R is hydrogen, loweralkyl or loweralkylcarbonyl; R.sub.1 is hydrogen, loweralkyl, loweralkylcarbonyl, aryl, diloweralkylaminoloweralkyl, arylloweralkyl, diarylloweralkyl, oxygen-bridged arylloweralkyl, or oxygen-bridged diaryllowerallyl; A is a direct bond or (CHR.sub.3).sub.m, m being 1-3; X is hydrogen, loweralkyl, cycloalkyl, loweralkoxy, halogen, hydroxy, nitro, trifluoromethyl, formyl, loweralkylcarbonyl, arylcarbonyl, --SH, loweralkylthio, --NHCOR.sub.4 or --NR.sub.5 R.sub.6, R.sub.4 being hydrogen or loweralkyl, and R.sub.5 and R.sub.6 being independently hydrogen, loweralkyl or cycloalkyl; Y is O, S or NR.sub.7 ; and each R.sub.2, each R.sub.3 and R.sub.Type: GrantFiled: January 10, 1991Date of Patent: February 14, 1995Assignee: Hoechst-Roussel Pharmaceuticals IncorporatedInventors: Gregory M. Shutske, Richard C. Effland
-
Patent number: 5258378Abstract: The invention relates to a compound of formula (I) ##STR1## in which R.sup.1 and R.sup.2 are each hydrogen, halo, hydroxy, nitro, C.sub.1-4 alkylcarbonyl, hydroxy-C.sub.1-4 alkyl, R.sup.3 is hydrogen or optionally substituted phenylsulphonyl, R.sup.4 is optionally substituted phenyl, benzofuranyl or dihydrobenzofuranyl, and R.sup.5 is hydrogen or C.sub.1-4 alkyl; and salts thereof. These compounds are useful dopaminergic agents.Type: GrantFiled: November 19, 1991Date of Patent: November 2, 1993Assignee: Lilly Industries LimitedInventors: Barry P. Clark, Graham H. Timms, David E. Tupper
-
Patent number: 5240934Abstract: Quinoline derivatives of the formula, ##STR1## wherein >A represents a group >N--(CH.sub.2).sub.n --, >C.dbd., >C.dbd.CH(CH.sub.2).sub.n --, or >CH(CH.sub.2).sub.n --, wherein n is an integer of 0-7; Y represents a group >C.dbd.O or >CHOH, R.sup.1 is a hydrogen atom, a halogen atom, an alkyl group, an alkoxy group, or an alkylthio group, R.sup.2 is a hydrogen atom, a halogen atom, an alkyl group, a hydroxy group, an alkoxy group, a phenyl group which may have a substituent, a phenoxy group, an alkanoyloxy group, or an amino group which may have a substituent, R.sup.3 is a hydrogen atom, a halogen atom, an alkyl group, or an alkoxy group, and m is an integer of 1-3. The compounds and their salts exhibit a superior anti-acetylcholinesterase activity with no side effects and are effective for the prevention or cure of senile dementia or memory disturbance.Type: GrantFiled: September 18, 1992Date of Patent: August 31, 1993Assignee: SS Pharmaceutical Co., Ltd.Inventors: Hiroshi Hasegawa, Kazuo Isomae, Takeshi Kotsugai, Noriaki Shioiri, Kumiko Sekine, Naokata Taido, Susumu Sato, Tadayuki Kuraishi
-
Patent number: 5198434Abstract: The invention concerns pharmaceutically useful compounds of the formula I, in which R.sup.1, R.sup.2, R.sup.3, R.sup.4, n, m, X, Y and Z have the various meanings defined herein, and their non-toxic salts, and pharmaceutical compositions containing them. The novel compounds are of value in treating conditions such as hypertension and congestive heart failure. The invention further concerns processes for the manufacture of the novel compounds and the use of the compounds in medical treatment.Type: GrantFiled: February 11, 1992Date of Patent: March 30, 1993Assignee: Imperial Chemical Industries PLCInventors: Robert H. Bradbury, David A. Roberts
-
Patent number: 5091384Abstract: Quinolone compounds of the general formula ##STR1## pharmaceutical compositions active against bacterial infections containing such compounds, processes for the manufacture of the quinolone compounds and the compositions and the use of the quinolone compounds for the manufacture of pharmaceutical compositions for the treatment of bacterial infections.Type: GrantFiled: October 19, 1990Date of Patent: February 25, 1992Assignee: Korea Research Institute of Chemical TechnologyInventors: Wan J. Kim, Myung H. Park, Jong H. Oh, Myung H. Jung, Bong J. Kim
-
Patent number: 5089621Abstract: Diazabicycloamine compounds of the general formula I and their acid salts ##STR1## wherein m represents an integer of 1 to 3,n represents 1 or 2, andR.sub.1 or R.sub.2 represents hydrogen or lower alkyl group, a process for their manufacture and their use for the preparation of novel quinolone compounds having excellent antibacterial activity.Type: GrantFiled: October 19, 1990Date of Patent: February 18, 1992Assignee: Korea Research Institute of Chemical TechnologyInventors: Wan J. Kim, Myung H. Park, Jong H. Oh